PMID: 15338851Sep 2, 2004Paper

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder

Pharmacotherapy
Alisa K ChristmanJohn S Markowitz

Abstract

Atomoxetine is the first nonstimulant drug approved by the United States Food and Drug Administration (FDA) for the treatment of attention-deficit-hyperactivity disorder (ADHD), and the only agent approved by the FDA for the treatment of ADHD in adults. Atomoxetine is a norepinephrine transport inhibitor that acts almost exclusively on the noradrenergic pathway. Its mechanism of action in the control and maintenance of ADHD symptoms is thought to be through the highly specific presynaptic inhibition of norepinephrine. Clinical trials to evaluate the short-term effects of atomoxetine in children and adults have shown that atomoxetine is effective in maintaining control of ADHD. Likewise, long-term trials have determined that atomoxetine is effective in preventing relapse of ADHD symptoms without an increase in adverse effects. A comparative trial of atomoxetine with methylphenidate in school-aged children indicated similar safety and efficacy without the abuse liability associated with some psychostimulants. The most commonly reported adverse effects in children and adolescents are dyspepsia, nausea, vomiting, decreased appetite, and weight loss. The rates of adverse events in the trials were similar for both the once- and twice...Continue Reading

References

Jan 1, 1985·Progress in Neuro-psychopharmacology & Biological Psychiatry·R W Fuller, D T Wong
May 1, 1985·Journal of Clinical Pharmacology·N A FaridL Lemberger
Aug 1, 1995·Journal of Clinical Psychopharmacology·T E WilensJ Prince
May 20, 1998·The American Journal of Psychiatry·T SpencerL Seidman
Jan 5, 2001·European Child & Adolescent Psychiatry·J Biederman, T Spencer
Feb 7, 2001·The American Journal of Psychiatry·T E WilensA Parekh
Feb 21, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Barbara J RingSteven A Wrighton
Mar 29, 2002·American Journal of Medical Genetics·Cathy L BarrJames L Kennedy
Jul 11, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Christopher J KratochvilDavid Michelson
Nov 5, 2002·Journal of Clinical Pharmacology·Donna J BelleJennifer W Witcher
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Frank P BymasterKenneth W Perry
Nov 29, 2002·Pediatrics·Joseph BiedermanUNKNOWN Atomoxetine ADHD Study Group
Dec 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·John-Michael SauerKarl A Desante
Jan 28, 2003·Biological Psychiatry·David MichelsonDenái Milton
Mar 7, 2003·Clinical Pharmacology and Therapeutics·Stephan A ChalonYves Horsmans
Jun 14, 2003·Journal of Child and Adolescent Psychopharmacology·Jennifer W WitcherJoseph Biederman
Nov 12, 2003·The Journal of Pharmacology and Experimental Therapeutics·John-Michael SauerJennifer W Witcher

❮ Previous
Next ❯

Citations

Aug 4, 2005·Psychopharmacology·Ulrich MüllerTrevor W Robbins
Apr 21, 2007·Psychopharmacology·Andrea R VansickelCraig R Rush
Apr 26, 2006·Cellular and Molecular Neurobiology·Piotr PopikAnthony S Basile
Jan 13, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Motoyasu YamashitaIchiro Sora
Nov 15, 2013·The New England Journal of Medicine·Nora D Volkow, James M Swanson
Jun 7, 2006·Acta Paediatrica·Sylvie Granon, Jean-Pierre Changeux
Dec 14, 2012·Journal of Child and Adolescent Psychopharmacology·Simona RuggieroAnnalisa Capuano
Apr 1, 2005·Current Opinion in Pediatrics·Alison Schonwald
Sep 9, 2006·The Australian and New Zealand Journal of Psychiatry·Pushpal Desarkar, Vinod K Sinha
Jul 3, 2009·International Journal of Clinical Practice·S PrasadS E Libretto
Nov 14, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·D DevosL Defebvre
Feb 16, 2006·CNS Drugs·Jud Staller, Stephen V Faraone
Dec 31, 2005·Indian Journal of Medical Sciences·S Karande
Jun 5, 2014·Brain : a Journal of Neurology·Angie A KehagiaTrevor W Robbins
Feb 6, 2014·Journal of Child and Adolescent Psychopharmacology·Esra Guney, Ozden Sukran Uneri
Jul 16, 2014·Journal of Child and Adolescent Psychopharmacology·Chia-Chien LiuYing-Sheue Chen
Feb 4, 2006·The Journal of Head Trauma Rehabilitation·David L Ripley
Aug 1, 2006·Expert Review of Pharmacoeconomics & Outcomes Research·Louis S MatzaJoseph A Johnston
Jul 16, 2014·Expert Opinion on Drug Metabolism & Toxicology·John S Markowitz, Bryan J Brinda
Apr 12, 2007·Expert Opinion on Pharmacotherapy·Richard H Weisler
Mar 30, 2005·Expert Opinion on Drug Safety·Sunke HimpelAribert Rothenberger
Sep 7, 2011·Pharmacology & Therapeutics·James A Young
Sep 1, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Grazia Dell'AgnelloUNKNOWN LYCY Study Group
Mar 31, 2009·Bioorganic & Medicinal Chemistry Letters·An T VuDarlene C Deecher
Nov 29, 2008·Bioorganic & Medicinal Chemistry Letters·James R ManningHuw M L Davies
Jul 24, 2007·Biological Psychiatry·Samuel R ChamberlainBarbara J Sahakian
Nov 26, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Dushad RamIyshwarya Rajalakshmi
Feb 24, 2007·Neuroscience and Biobehavioral Reviews·Michael A van der Kooij, Jeffrey C Glennon
Feb 11, 2011·Synapse·Kirsty DanielsonBronwyn M Kivell
Apr 12, 2013·Journal of Cardiovascular Electrophysiology·Henri Roukoz, David G Benditt
Sep 20, 2011·Developmental Cognitive Neuroscience·Rachel E CainJill A McGaughy
Sep 5, 2006·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Hao-Jie ZhuJohn S Markowitz
Oct 10, 2006·Brain Research Bulletin·N T Bello, A Hajnal
Jul 13, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Christoph U Correll, Harold E Carlson
Jul 22, 2016·Organic & Biomolecular Chemistry·Yufeng LiuWanbin Zhang
Sep 15, 2016·Organic Letters·Duanyang KongGuohua Hou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.